Dr. C. Ronald Kahn, a medical professor at Harvard University and a professor of Joslin Diabetes Center in Harvard, New York Times He has many patients who are reluctant to inject himself. He said that the medicine would be “favored by most people.”
Some companies are trying to develop weight loss drugs, assuming that sales of obesity can be $ 150 billion ($ 235 billion) over the next few years. The latest data is firmly led in competition for effective oral drugs that Lilly can compete with injections.
Ozempic, approved for diabetes in 2017, is designed to target a chapter hormone called GLP-1.
It competes with LILLY’s injectable Tirzepatide-a brand name, and has been sold in Zepbound for obesity with Mounjaro for obesity. This mimics the second hormone of GLP-1 and GIP, showing a 22 %weight loss over 72 weeks.
Like Ozempic, Orforglipron aims at GLP-1, but unlike hormonal imitation peptides, synthetic small molecular drugs.
Pills such as Orforglipron are simpler manufacturing, which can mean a wider access to effective weight loss options. There is no need for injection packaging and no need to keep it refrigerated.
Dr. Sean Wharton, director of Wharton Medical Clinic in Burlington, Ontario, said, “It is easy to make in the factory and can be shipped anywhere. New York Times.
Lilly’s safety profile in Orforglipron matches other GLP-1 and continued to worry about potential stumbling blocks for sales.
Last year, Ozempic producer NOVO NORDISK’s US -listed stocks fell again on Thursday.Credit transaction: AP
Kevin Gade, the chief operating officer of Bahl & Gaynor, owned by Lilly Shares, “The data is fantastic in terms of efficacy.
Lily said he would report data from other tests on weight management pills this year. By the end of this year, we plan to be approved by regulatory agencies around the world for weight loss and next year.
Gade said, “This test alone is very good, but it goes very well with the test of obese patients.
According to the late test, 13 %to 18 %of the patients who administered the drug compared to 2 %of the placebo, experienced the nausea over dose. The rate of diarrhea was 19 %to 26 %and 14 %vomiting.
“This results firmly verifying the allowable profiles of Orforglipron.”
On Monday, Pfizer stopped the development of danuglipron, a test patient, after the drug treatment was suspended, and experimental weight loss pills danuglipron.
Lily said there was no liver safety signal at the trial.
The company said that 8 %of patients in Orforglipron were suspended due to side effects.
Loading
Over time, the level of HBA1C, the scale of blood sugar, has decreased 1.6 % from 1.3 % over the dose.
LILLY showed that the weight loss of 7.9 %decreased by 4.7 %from 3 millimeters to 4.7 %, 12mm from 6.1 %and 36 millimeters. Positive patients were lost 1.6 %.
Lilly said he was convinced of the ability to launch Orforglipron worldwide without supply constraints.
Reuters
